News

Published on 3 Jan 2024 on Zacks via Yahoo Finance

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why


Article preview image

Shares of C4 Therapeutics, Inc. CCCC or C4T have skyrocketed 310.1% in the past three months compared with the industry’s increase of 9.8%.

The clinical-stage biopharmaceutical company is engaged in developing a new generation of medicines that harness targeted protein degradation. C4T utilizes its proprietary TORPEDO platform to design, analyze and predict degrader performance.

In December 2023, CCCC entered into an exclusive licensing and collaboration agreement with pharma giant Merck MRK to discover and develop degrader-antibody conjugates (“DACs”) with an initial focus on one oncology target.

NASDAQ.CCCC price evolution
NASDAQ.PBYI price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Is Puma Biotechnology, Inc. (NASDAQ:PBYI) A High Quality Stock To Own?

Many investors are still learning about the various metrics that can be useful when analysing a s...

Simply Wall St. via Yahoo Finance 29 Apr 2024

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Shares of Viatris, Inc. VTRS lost 4.8% in the last three trading sessions after the company repor...

Zacks via Yahoo Finance 5 Mar 2024

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript February 29, 2024 Puma Bi...

Insider Monkey via Yahoo Finance 2 Mar 2024

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Could Be 47% Below Their Intrinsic Value Estimate

Key Insights Puma Biotechnology's estimated fair value is US$11.07 based on 2 Stage Free Cash Flo...

Simply Wall St. via Yahoo Finance 2 Mar 2024

Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 1 Mar 2024

Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023

Net Income: PBYI reported a net income of $12.3 million in Q4 2023, a significant improvement fro...

GuruFocus.com via Yahoo Finance 1 Mar 2024

Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates

Puma Biotechnology, Inc. PBYI reported fourth-quarter 2023 adjusted earnings of 31 cents per shar...

Zacks via Yahoo Finance 1 Mar 2024

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

Novavax, Inc. NVAX reported a fourth-quarter 2023 loss of $1.44 cents per share, much wider than ...

Zacks via Yahoo Finance 29 Feb 2024

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance Biopharma, Inc. TBPH reported fourth-quarter 2023 adjusted net income of 3 cents per s...

Zacks via Yahoo Finance 27 Feb 2024

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

We expect investors to focus on Puma Biotechnology, Inc.’s PBYI progress with its sole marketed d...

Zacks via Yahoo Finance 27 Feb 2024